BioVie Presents Phase 2 ADDRESS-LC Study Results for Bezisterim in Long COVID

Article summary

BioVie Inc. presented clinical data from its Phase 2 ADDRESS-LC study evaluating the investigational oral therapy bezisterim (NE3107) for the treatment of Long COVID at the American Neurological Association Annual Meeting.